论文部分内容阅读
目的观察不同GADAb滴度的T2DM患者C-P水平及并发症等指标。方法 189例患者根据GADAb滴度分为抗体阳性组78例和抗体阴性组111例,进一步对阳性组以滴度划分亚组,比较临床指标,并行GADAb与其他指标的相关性分析及多元回归分析。结果 (1)抗体阳性组FC-P水平低于抗体阴性组[(1.63±0.97)vs(1.84±0.99)ng/ml,P<0.01],FPG、2hPG高于抗体阴性组[(12.61±0.79)vs(9.74±3.67)mmol/L;(16.97±7.24)vs(13.59±5.32)mmol/L,P<0.05或P<0.01],高血压和高血脂病变的发生率低于抗体阴性组(30.15%vs 50.05%,45.80%vs 69.81%,P<0.05)。(2)不同抗体滴度划分的亚组间FC-P水平、高脂血症,糖尿病神经病变和DR发生率比较,差异均有统计学意义(P<0.05)。结论 T2DM患者不同GADAb滴度的临床特征有所不同,出现GADAb阳性高滴度时,应注意胰岛功能的保护和微血管并发症的筛查。
Objective To observe the C-P levels and complications of T2DM patients with different GADAb titers. Methods A total of 189 patients were divided into antibody-positive group (n = 78) and antibody-negative group (n = 111) according to the GADAb titer. The positive group was further divided into two subgroups according to the titer of GADAb. The correlation between GADAb and other indexes and multivariate regression analysis . Results (1) The level of FC-P in antibody positive group was lower than that in antibody negative group [(1.63 ± 0.97) vs (1.84 ± 0.99) ng / ml, P <0.01] (9.74 ± 3.67) mmol / L, (16.97 ± 7.24) vs (13.59 ± 5.32) mmol / L respectively, P <0.05 or P <0.01]. The incidence of hypertension and hyperlipidemia was lower than that of antibody negative group 30.15% vs 50.05%, 45.80% vs 69.81%, P <0.05). (2) There was significant difference in FC-P level, hyperlipidemia, diabetic neuropathy and DR incidence between subgroups with different antibody titers (P <0.05). Conclusion The clinical features of different GADAb titers in patients with T2DM are different. In the presence of GADAb-positive high titers, the protection of islet function and the screening of microvascular complications should be noticed.